Klotho, ageing and the failing kidney by Buchanan, S. et al.
REVIEW
published: 27 August 2020
doi: 10.3389/fendo.2020.00560
Frontiers in Endocrinology | www.frontiersin.org 1 August 2020 | Volume 11 | Article 560
Edited by:
James Harper,













This article was submitted to
Endocrinology of Aging,
a section of the journal
Frontiers in Endocrinology
Received: 11 June 2020
Accepted: 09 July 2020
Published: 27 August 2020
Citation:
Buchanan S, Combet E, Stenvinkel P
and Shiels PG (2020) Klotho, Aging,
and the Failing Kidney.
Front. Endocrinol. 11:560.
doi: 10.3389/fendo.2020.00560
Klotho, Aging, and the Failing Kidney
Sarah Buchanan 1, Emilie Combet 2, Peter Stenvinkel 3 and Paul G. Shiels 1*
1Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom,
2 School of Medicine, Dentistry & Nursing, Human Nutrition, Glasgow Royal Infirmary, Glasgow, United Kingdom, 3Division of
Renal Medicine M99, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
Klotho has been recognized as a gene involved in the aging process in mammals for
over 30 years, where it regulates phosphate homeostasis and the activity of members
of the fibroblast growth factor (FGF) family. The α-Klotho protein is the receptor for
Fibroblast Growth Factor-23 (FGF23), regulating phosphate homeostasis and vitamin
D metabolism. Phosphate toxicity is a hallmark of mammalian aging and correlates
with diminution of Klotho levels with increasing age. As such, modulation of Klotho
activity is an attractive target for therapeutic intervention in the diseasome of aging; in
particular for chronic kidney disease (CKD), where Klotho has been implicated directly
in the pathophysiology. A range of senotherapeutic strategies have been developed
to directly or indirectly influence Klotho expression, with varying degrees of success.
These include administration of exogenous Klotho, synthetic and natural Klotho agonists
and indirect approaches, via modulation of the foodome and the gut microbiota. All
these approaches have significant potential to mitigate loss of physiological function
and resilience accompanying old age and to improve outcomes within the diseasome
of aging.
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INTRODUCTION
In 1997 Kuro-o et al. (1) reported a mutant mouse displaying a phenotype similar to that of
premature aging in humans. The phenotype of shortened lifespan, multiple organ degeneration,
vascular calcification (VC), cardio-vascular disease (CVD) and frailty were attributed to the
abolished expression of the klotho gene, named after the Greek goddess of fate, κλωθ ′ω, who spun
the thread of life (1). Subsequent murine models, deficient in Klotho, displayed both an accelerated
aging phenotype and abnormal phosphate and mineral regulation (2, 3).
Klotho has subsequently been characterized as one of a family of related proteins. These are all
single-pass transmembrane proteins that include α-, β-, and g- Klotho isoforms (3–5), the latter
two discovered based on their homology with α-klotho (6, 7). β -Klotho is mainly expressed in the
liver, but is also found in the kidney, gut and spleen. It regulates the activity of members of the
fibroblast growth factor (FGF) family, including FGF-21 and FGF-19.g-Klotho is expressed in the
skin and the kidney and has yet to be ascribed defined functions (3, 7). α-Klotho comprises five
exons and structurally its cognate protein is composed of a large extracellular domain followed by a
transmembrane domain and a small domain of 11 residues comprising the intracellular C-terminus
(8, 9). The extracellular domain comprises two repeat sequences termed KL1 and Kl2 which are
generated by full-length transcript splicing and can be cleaved by the metalloproteases ADAM-10
and ADAM-17. Cleavage of the extracellular domain results in a soluble form of Klotho being
released (8). Soluble Klotho is the main functional form in the circulation (10, 11) and is detected
in the blood, urine, and cerebrospinal fluid (11–14).
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Following the discovery of fgf23 deficient mice displaying
an identical aging phenotype to Klotho deficient mice, the
Klotho protein was functionally identified as a receptor for
Fibroblast Growth Factor-23 (FGF23) (2). FGF23 is a bone-
derived hormone with a role in regulating phosphate excretion,
which negatively regulates Vitamin D levels (15). Klotho is
required for high affinity binding of FGF23 to its receptor FGFR1
(16); it is the resultant binary complex that constitutes the
physiological receptor for FGF23 (17).
The Klotho protein that was identified as the FGF23 co-
receptor was the α-Klotho isoform, which hereafter is termed
Klotho. Klotho is expressed mainly on the cell surface membrane
of proximal and distal renal tubules (18–20), though it is also
found in the choroid plexus in the brain (21).
WHY KLOTHO IS IMPORTANT IN AGING
Klotho regulates many pathways involved in aging processes,
such as the regulation of phosphate homeostasis, insulin
signaling and Wnt signaling (5, 22). Additionally, Klotho also
affects intracellular signaling pathways including p53/p21, cAMP,
protein kinase C (PKC) and TGF-β (23, 24).
Klotho expression levels and its circulating level decline
during aging. In humans, Klotho deficiency features medial
calcification, intima hyperplasia, endothelial dysfunction,
arterial stiffening, hypertension, impaired angiogenesis, and
vasculogenesis (i.e., characteristics of early vascular aging) (25).
As Klotho-deficient phenotypes have been attenuated and
rescued by Klotho gene expression, or supplementation, it is
suggestive that Klotho has a protective effect with regard to the
vasculature (26).
Mice deficient in Klotho exhibit a phosphate imbalance and
hyperphosphatemia due to impaired urinary phosphate
excretion, but significantly develop a complex progeric
phenotype including poor growth, atrophy of multiple organs,
vascular calcification (VC), sarcopenia, cardiac hypertrophy and
fibrosis, cognitive impairment, and shortened lifespan (1, 2, 5).
Consequently, Klotho knock-out mice display severe vascular
disease, with widespread VC, endothelial dysfunction, and
progressive atherosclerosis accompanied by hypervitaminosis D,
hypercalcemia, and hyperphosphatemia (27).
As Klotho has been regarded as an anti-aging gene, in order
to more fully understand how Klotho might impact age-related
disease, this review focuses on what we actually mean by the
aging process, its relevance to chronic kidney disease (CKD) as a
disease of accelerated aging, and how this is impacted by Klotho.
Furthermore, we discuss how modulation of Klotho might be
exploited to mitigate the effects of the diseasome of aging.
Aging
Rather than simply being a collection of morbidities arising
during the final decades of life, aging is an active process across
the entire life-course. It has been described as an accumulation
of physiological and molecular deficits accruing at different
rates, both within different tissues and organs in the same
individual and between different individuals (28). Aging leads to
a segmental and progressive loss of physiological function and
physical capability over time, resulting in relative physiological
frailty and loss of resilience (29–33). It is regulated actively by
distinct biochemical pathways and has been characterized by a
series of molecular and cellular hallmarks, which are common
across taxa (33). These hallmarks comprise genomic instability,
telomere attrition, epigenetic dysregulation, loss of proteostasis,
dysregulated nutrient sensing, mitochondrial dysfunction,
cellular senescence, with an accompanying senescence associated
secretory phenotype (SASP), stem cell exhaustion, and altered
intercellular communication (33).
Aging and Phosphate—FGF23-Klotho Axis
In mammals, aging has a number of distinct additional
features to its common hallmarks, comprising phosphate toxicity,
diminished global Nrf2 expression, and microbial dysbiosis (34).
These features are inherent in an associated “diseasome of aging,”
where dysregulated aging processes are a common underpinning
feature of individual morbidities. These reflect an individual’s
“burden of lifestyle” and the generation of allostatic (over)load
at a molecular and cellular level, with concomitant loss of
physiological resilience and capability (34, 35). It is within this
framework that phosphate makes a significant contribution and
why its interaction with Klotho is important.
Serum phosphate (Pi) levels shows an exceptionally strong
negative correlation with lifespan in mammals (32, 36),
Phosphate metabolism and reabsorption by the kidney is
regulated via interaction between the kidney, bone, and gut,
controlled by a cross-regulating endocrine network comprising
para-thyroid hormone (PTH), vitamin D, FGF-23, and Klotho
(5). As mice lacking α-Klotho, or FGF23, show phosphate
retention (37), this suggests that this signaling axis is essential for
Pi homeostasis. Several studies have shown that FGF23 increases
urinary excretion of Pi and indirectly suppresses intestinal Pi
absorption via down-regulation of vitamin D3 (15, 38, 39).
Unsurprisingly, both FGF23 and Klotho deficient mice display
a progeric phenotype and associated abnormal Pi regulation
(2, 3). Additionally, Klotho deficient mice also display high
FGF23 levels (40), and as a consequence of loss of Klotho
expression may result in maladaptive signaling downstream of
the FGF-receptor (FGFR) that may contribute to CKD associated
co-morbidities, in particular cardiovascular co-morbidity. For
example, this may result in a switch in FGF23-induced signaling
in cells expressing FGFR4, but not α-Klotho (40). Critically,
in support of this thesis, specific FGFR4 blocking antibodies
have been demonstrated to attenuate left ventricular hypertrophy
(LVH) in 5/6 nephrectomized rats, emphasizing that FGFR4
activation is a critical patho-mechanistic feature underlying LVH
in states of α-Klotho deficiency and elevated levels of FGF23
excess (41).
Pertinent to these observations are observations of Klotho
signaling independent of FGFR4 in the heart, liver, and lung
(40, 42). In the kidney context dependent signaling has also been
reported; neither FGFR3 nor FGFR4 is the principal mediator
of FGF23 effects in the proximal tubule, but co-localization of
FGFR1 and Klotho indicates that the effector site for FGF23 may
be in the distal tubule (43). A reduction in tubular phosphate
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reabsorption may enable hyperphosphatemia to occur at earlier
stages of CKD.
It is unclear how changes in serum Pi are detected, however,
it is thought to involve sensing of calciprotein particles (CPPs),
which are colloids comprised of calcium-Pi bound to fetuin A,
a circulating inhibitor of vascular calcification (5, 37, 44). In
proximal tubules, blood-borne FGF23 binds to α-Klotho-FGF
receptors 1c, 3c, and 4 complexes, directly activating ERK 1/2
and SGK-1 signaling cascades, leading to down-regulation of
the Na/H exchange regulatory cofactor NHERF-1 expression,
localized to the brush border membrane of proximal tubular
cells, a major site of Pi reabsorption (38). Down-regulation of
NTP2A results in decreased Pi reabsorption in proximal tubules
and increased urinary Pi excretion (8, 45). Active vitamin D and
PTH both induce FGF23 expression (46, 47). Vitamin D has been
shown to induce receptor hetero-dimerization with the retinoid
receptor, resulting in the up-regulation of vitamin D responsive
element target genes including FGF23 (48). PTH binding to
its receptor results in PKA activation and the suppression of
sclerostin, antagonizing the WNT signaling pathway and the
suppression FGF23 expression (49). Serum levels of both active
vitamin D and PTH are both reduced by FGF23, whilst FGF23
suppresses the synthesis of active vitamin D by up-regulation
of Cyp24a1, which encodes 24-hydroxylase, responsible for
the conversion to inactive vitamin D by a Klotho dependent
mechanism (Figure 1). Cy27b1 expression, which converts the
D3 form to the active form of vitamin D, is downregulated. PTH
is suppressed via both α-Klotho dependent and independent
pathways. α-Klotho is expressed in the parathyroid gland and
FGF23 suppresses both the expression and secretion of PTH
(46). Serum levels of FGF23 correlates with both serum Pi and
calcium levels and evidence suggests that both Pi and calcium
are required to stimulate FGF23 levels by osteocytes (50, 51).
Notably, hyperphosphatemia has been shown to induce DNA
damage in vascular smooth muscle cells, resulting in cellular
senescence, which further contributes to the premature aging
process observed with Klotho dysregulation or loss (3, 52). This
has implications for clinical conditions where Klotho may play a
role. This is now discussed below with specific reference to CKD
as a disease of aging.
CKD and Aging
CKD is part of the diseasome of aging and displays an
overlapping phenotype with Klotho-deficient mice. It has been
suggested that Klotho function is tightly correlated with the
pathogenic mechanisms underpinning CKD (18, 53–55).
CKD is a progressive systemic disease that affects 10–12%
of the population (56). The prevalence of CKD has increased
markedly over the past decades due to an aging population
worldwide and an increase in incidence of obesity and type-2
diabetes; a significant driver of CKD (57). Progressive kidney
damage leads to an increased number of systemic complications,
hallmarked by persistent (chronic) low-grade inflammation,
including hyperphosphatemia, CVD, anemia, hypertension,
mineral-bone disorders, muscle wasting, osteoporosis, increasing
frailty, and anemia (58). In earlier stages of CKD, a reduction
in the reabsorption of Pi by the kidney triggers increased FGF-
23 secretion that promotes renal Pi secretion. However, when
patients reach CKD stage 3 systemic hyperphosphatemia usually
occurs, which contributes to systemic inflammation and VC
leading to early vascular aging (EVA) (59). Hyperphosphatemia
promotes endothelial dysfunction (60) and induces expression
of the pro-inflammatory NFkB pathway (61). Impaired kidney
function results in the accumulation of systemic nitrogenous
compounds which leads to persistent inflammation involving
both immune activation and immunosuppression (62). The
uremic phenotype within CKD is characterized by an increased
frequency of associated age-related complications, such as
vascular stiffening, osteoporosis, muscle wasting, depression,
cognitive dysfunction, and frailty (58, 63). A model of four
key mechanisms has been proposed for the pathogenesis of
premature aging based upon: (i) a persistent increase in allostatic
load owing to oxidative stress, inflammation (inflammageing),
and disturbances in sympathetic-vagal balance and circadian
rhythm; (ii) activation of the stress resistance response which
contributes to inhibition of anabolic pathways, increased protein
catabolism, and tissue atrophy; (iii) disease-associated alterations
that directly promote the aging process; (iv) defective anti-
agingmechanisms (58). If allostatic responsemechanisms remain
chronically activated, systemic complications then follow.
Chronic low-grade inflammation also contributes to the
premature aging phenotype in CKD (64) and other “burden
of lifestyle” diseases, such as chronic obstructive pulmonary
disease (COPD), chronic heart failure (CHF), and rheumatoid
arthritis (RA). These diseases exhibit phenotypic similarities that
reflect premature biological aging (58). Correspondingly, features
of cellular aging such as telomere attrition and accumulation
of p16 positive senescent cells, are characteristic of CKD
and other conditions within the diseasome of aging (8, 29).
Unsurprisingly therefore, uremic inflammation resembles the
systemic inflammation associated with aging effects on the
immune system, termed “inflammageing” and similar pathogenic
mechanisms have been observed in aging and CKD, specifically
premature immunological aging (65). Associated with this is
immunosenescence, which arises due to the chronic depletion
of naïve T cells, B cells, and dendritic cells, an expansion of
memory T cells, particularly pro-inflammatory CD4+CD28–
T cells, along with impaired neutrophilic phagocytic capacity
and the loss of reno-protective factors, including Klotho and
bone-morphogenic proteins, vascular rarefaction, and increased
oxidative stress (58, 66). Reactive oxygen species (ROS) levels
can also regulate signaling via the stress activated kinases, p38,
and JNK. These pathways are often activated in aged tissues and
contribute to inflammation and cellular senescence (67–70).
Along with systemic oxidative stress, mitochondrial
dysfunction is a partner in crime, that links together with
inflammation and the effects of uremic toxins to accelerate the
aging process (44, 58, 71, 72). Two protein-bound uremic toxins,
indoxyl sulfate (IS), and p-cresyl sulfate (pCS), not removed
by conventional dialysis, are potent inducers of inflammation,
oxidative stress, and vascular endothelial cell injury (73) and
contribute to both the progression of renal impairment (74)
and associated co-morbidities (75). Advanced Glycation End
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FIGURE 1 | Schematic representation of the role of Klotho in the regulation of bone and mineral metabolism.
Products (AGE), which are also uremic toxins, accumulate
in CKD, leading to mitochondrial dysfunction, elevated ROS
production and structural changes through macro-molecular
cross-linking. Consequently, the AGE axis induces renal cytosolic
oxidative stress and inflammation (76, 77) leading to cell and
tissue damage and the induction of premature senescence in
proximal tubular epithelial cells and mesangial cells in vivo
(78, 79).
A hallmark of uremic inflammation is the activation and
defective regulation of the innate immune system. Abnormal
activation of the innate immune system, especially the increased
activation of monocytes, contributes to systemic inflammation
via increased synthesis of pro-inflammatory cytokines. Several
circulating pro-inflammatory markers have been reported to
gradually alter in CKD as renal function fails, including IL-
6, fetuin A, and TNF, which have previously been associated
with renal aging and disease (80). Activation of inflammasome
signaling by cytokines, ROS, and Damage-associated molecular
patterns (DAMPs) results in an increase in Il-1β and IL-18,
leading to an imbalance in the regulation of epigenetic mediators
of aging such as miRNAs. For example oxidative stress has
been shown to suppress Klotho expression in HK-2 cells via
the induction of miR-200c (81). Deregulated TGFβ has also
been shown to epigenetically induce Klotho deficiency and
renal fibrosis in mice via induction of a number of miRNAs,
including miR-21, miR-192, miR-491, miR-382, miR-377, miR-
214, and miR-433 (82). The resulting imbalance of pro- and anti-
inflammatory macrophages, and mitochondrial damage leads to
the chronic systemic uraemic inflammation associated with CKD
(44). Additionally, a consequential increase in synthesis of pro-
inflammatory cytokines and chemokines by senescent cells, as
part of the senescence-associated secretory phenotype (SASP),
exacerbates both the inflammatory burden and dysregulated
aging processes in CKD (44).
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KLOTHO IN CKD
The phenotypic characteristics of genetic Klotho deficiency,
such as bone disease, VC, CVD increased FGF23 levels,
hyperphosphatemia, and premature mortality, resembles the
uremic accelerated aging phenotype in man (58, 83). In
keeping with these observations, Klotho deficiency in CKD
has been reported to enhance renal tubule and vascular
cell senescence leading to defective endothelial function and
impaired vasculogenesis (84). Current literature supports such a
thesis, and has indicated that the development and progression
of CKD is significantly associated with a dysregulated FGF23-
Klotho pathway, resulting in hyperphosphatemia and endothelial
dysfunction (8, 18, 53–55). Phosphate retention, progressive
hyperphosphatemia, rising FGF23 levels and low Klotho
expression are all observed in patients with progressive CKD
and are associated with age-associated CVD. Correspondingly,
more recent studies have reinforced these observations and
shown that the development and progression of CKD associates
with a decline in Klotho in animal models (18, 53–55, 85–
87). Kidney specific Klotho deficiency has been observed to
reproduce the phenotype of Klotho deficient animals, displaying
very low circulating Klotho and high circulating FGF23 levels
(88). Specific deletion of Klotho in distal tubules has also been
reported to inhibit the increase in renal Pi excretion in response
to FGF23 (89), which suggests that Klotho deficiency limits its
regulation of FGF23 production and that hyperphosphataemia,
which usually become evident in CKD stage 3, remains the
principal regulator of FGF23 secretion in CKD (90).
Dysregulation of the FGF23—α-Klotho network already
occurs at earlier CKD stages, where abnormal levels of calcium
and phosphate, inflammation, increased apoptosis, and depletion
of calcification inhibitors results in the promotion of an active
calcification process (91, 92). As nephron numbers decrease with
age and renal damage, there is a resultant increase in Pi excretion
per nephron via up-regulation of FGF23 observed in all CKD
patients, causing a lowering of active vitamin D levels in the
serum followed by an increase in PTH (5, 8, 44, 93, 94).
Recent research has indicated that Klotho may be involved
in the manifestation of comorbidities associated with CKD.
Klotho, for example, is expressed in the choroid plexus of the
brain and controls the brain-immune system interface in the
choroid plexus (21). As the uremic phenotype is associated
by behavioral impairments, such as dementia, depression and
cognitive deficits (95) and Klotho enhances oligodendrocyte
maturation and myelination of the CNS (96), the low Klotho
state of CKD may contribute to the common manifestations
of central nervous system dysfunction in CKD. The specific
role of the low Klotho state in the complicated scenario
of uremic cognitive dysfunction (97) and disruption of the
blood-brain barrier when renal function declines (98) deserves
further studies.
Hypertension, an almost ubiquitous feature of CKD that
contributes to both progression of CKD and CVD, may in part be
related to Klotho deficiency. Mice deficient in Klotho have been
reported to develop salt-sensitive hypertension after high sodium
challenge (99) and a Klotho single nucleotide polymorphism
with salt-sensitive hypertension has been described in adults with
newly diagnosed hypertension (100).
In the uremic milieu lower Klotho levels may be exacerbated
by the accumulation of protein bound uremic toxins, that
epigenetically dysregulate Klotho gene expression and by an
increase in TNF, which impairs Klotho protein expression
(5, 29, 101). This relationship with inflammatory processes
appears to be mutually reciprocal. Klotho modulates anti-
inflammatory response in the kidney via a NF-κB mediated
pathway, while Klotho expression in turn, is down-regulated by
pro-inflammatory cytokines, such as TWEAK, again via an NF-
κB dependent mechanism. Thus, while NF-κB per se contributes
to the regulation of Klotho expression (102), Klotho however, in
turn down-regulates NF-κB (103) and inhibition of NF-κB has
been shown to reduce expression of several pro-inflammatory
cytokines and renal injury (104–106). Correspondingly, in
keeping with this thesis, Klotho depletion has also been shown
to contribute to increased inflammation in the kidney in a pre-
clinical murine model (107).
Klotho and Vascular Biology
Numerous studies have suggested that Klotho is critical for
vascular health and its therapeutic administration in CKD can
exert vasculo-protective effects. Vascular calcification develops
early in CKD and is associated with a decline in kidney
function and an up-regulation of Pi resulting in a high risk of
cardiovascular mortality and morbidity (8, 108–110).
Accordingly, Klotho deficiency in mice with CKD is paralleled
by the development of VC and the occurrence of high Pi levels. As
over-expression of Klotho enhances phosphaturia and improves
renal function, it is suggestive that dysregulation of Klotho
function is a key element in the development of VC (27, 55).
Zhao et al. (111) have demonstrated that up-regulation
of Klotho expression protects against VC in CKD, via the
inhibition of mTOR signaling in VSMC, in keeping with CKD
as a disease of accelerated aging (111, 112). Accordingly, the
stable delivery of soluble Klotho has been reported to reduce
chronic hyperphosphatemia and VC both in vitro and in vivo
(113). In support of these observations, soluble Klotho has been
demonstrated to directly suppress Pi uptake and mineralization
induced by high Pi in vivo, whilst administration of recombinant
Klotho increased soluble Klotho by vitamin D receptor agonists
(VDRA) treatment. Accordingly, the stable delivery of soluble
Klotho has been reported to reduce chronic hyperphosphatemia
and VC both in vitro and in vivo (113). This is in keeping
with data from other approaches to mitigate the effects of
hyperphosphatemia driven VC. Lau et al., have demonstrated
that in a mouse model of chronic kidney disease where
dietary phosphate loading induced aortic medial calcification,
administration of vitamin D receptor agonists (calcitriol or
paricalcitol) reduced aortic calcification and increased the
expression of the anti-calcification factor, osteopontin, in aortic
medial cells (27, 114).
CKD-mineral Bone disorder (CKD-MBD) and renal fibrosis
have both been associated with diminished Klotho expression.
Studies in a mouse model of CKD-MBD have indicated that loss
of Klotho expression is a key event in renal and bone injuries
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and that restoration of Klotho expression attenuated CKD
related bone defects (115). These observations are supported
by enhanced Klotho expression via differential promoter
demethylation, which has been demonstrated to protect against
kidney and bone injuries in a mouse CKD model (116). Renal
fibrosis, is also affected by Klotho expression levels. Renal
fibrosis occurs following incomplete healing of wounded kidney
tissue in the course of CKD, after chronic sustained injury.
It is characterized by glomerulosclerosis, tubular atrophy, and
interstitial fibrosis (117). A reduction in Klotho can both be a
result and cause of renal fibrosis and can promote a vicious
circle of RF generation and mitigation (118). A key regulator
of this renal fibrosis cycle in CKD is TGF-β, which stimulates
the accumulation of matrix proteins to induce ECM, inhibition
of matrix degradation and the regulation of myofibroblast
activation (119). In keeping with this thesis, murine models have
indicated that inhibition of Klotho increases TGF-β expression
and that TGF-β subsequently reduces Klotho expression via a
negative feedback loop (120). Induction of Klotho also directly
mitigates the effects of other pro-fibrotic factors, such as
Angiotensin II (Ang II) and basic Fibroblast growth factor 2
(bFGF2). Klotho has been reported to mitigate Ang II-induced
renal damage and suppress bFGF 2 expression in vivo (121) in
keeping with a proposed reno-protective role for Klotho via the
inhibition of multiple signaling pathways.
DISCUSSION
The weight of basic science, pre-clinical, and clinical evidence
suggests that modulation of Klotho function is an exciting and
viable target for therapeutic interventions. As such, it is a prime
therapeutic target for intervention in a range of diseases within
the diseasome of aging, including CKD (8, 122, 123). Given the
role of Klotho in the biology of aging, such interventions also
fall within the remit of senotherapies (i.e., therapeutic agents and
strategies to specifically target and mitigate the deleterious effects
of aspects of aging process).
As such, Klotho-mediated therapies may be classed as
geroprotective (i.e. mitigating or inhibiting the effects of
macromolecular damage leading to loss of cellular and
physiological resilience and function, including the effects of the
SASP), and senomorphic (i.e. suppression of senescence effects
without cytotoxicity). It is important to note, however, that the
context of their application and time in the life course applied
are key elements for any success. While most basic and pre-
clinical studies have focussed on mid- to end of life application,
data from early life interventions are sparse and require a more
robust evaluation. This is pertinent to the concept of antagonistic
pleiotropy, as aging is a continuous process occurring across the
life course, thus suggesting that the effects of any interventions
will be dependent on the context of the stage of the life course
at which they are applied. Cellular senescence is likely to be
subject to antagonistic pleiotropy, as senescent cells are not
desirable in young individuals, but are essentially anti-oncogenic
in the old. The potential for any intervention to generate
adverse effects, especially subtle epigenetic or cryptic effects, thus
needs evaluated from this perspective. Initial evidence, however,
suggests that most interventions appear to be well-tolerated and
have some beneficial effective. Indeed, over-expression of α-
Klotho has been reported to reverse the phenotype and extended
life-span in Klotho-deficient mice (11, 114, 124).
Targeting Klotho in CKD is particularly pertinent on a
number of fronts, Firstly, accurate detection of CKD at an
early stage has proven problematic and currently no biomarkers
are available which are suitably accurate, easily measured
and sensitive enough (125). Current diagnostics rely on a
GFR and urinary albumin:creatine ratio (UACR) (88). Thus,
a blind spot occurs in early stage CKD where the eGFR
and albuminuria are not above abnormal thresholds although
kidney damage is ongoing. Soluble Klotho starts to decline
in early CKD (Stage 2) (20). The decrease in Klotho in the
kidneys correlates positively with diminution of eGFR (126–
129), suggesting the decrease in soluble Klotho may accurately
mirror an eGFR decrease in patients. Thus, measuring Klotho
levelsmay provide earlier diagnosis (130). Secondly, standardized
functional assays to detect Klotho activity are still currently
lacking and several commercially available antibodies have been
reported as unspecific and to cross-react with other proteins
(131, 132). Thirdly, a number of strategies have been attempted to
modulate Klotho expression with the aim if clinically translating
findings. These strategies are illustrated in Figure 2 and are
now discussed.
Restoration of Klotho Levels and Activity
Administration of Exogenous Klotho
Several studies have suggested that pharmaceutical replacement
or supplementation of Klotho can improve complications
associated with CKD (8). Pre-clinical studies have indicated that
administration of soluble Klotho can reduce renal fibrosis (120),
VC (133), and EMT (134). Administration of soluble Klotho
has proven a safe and effective treatment for kidney injury
and preservation of renal function in early clinical studies (20,
135), though subsequent use of recombinant Klotho has yielded
equivocal results (136).
Reactivation of Endogenous Klotho
Activation of Klotho has been reported to reduce levels of
oxidative stress (137), improve mitochondrial function (137),
reduce renal fibrosis (138), and inflammatory burden (8).
Additionally it has been reported to mitigate the effects of
premature aging (137) and EVA (139). Several methods have been
explored to increase Klotho expression. These include:
(i) Demethylation of the Klotho promoter: Azuma et al.
have demonstrated the use of Azacytidine (Aza), a DNA
methyltransferase inhibitor, to increase Klotho expression
∼1.5- to 3-fold in vitro by modulation of Klotho promoter
expression (140). While this is feasible the laboratory, its
clinical translation is more challenging, given the broad
spectrum activities of Aza.
(ii) Deacylation: Inhibition of histone deacetylases using HDAC
inhibitors, such as trichostatin A or valproic acid have
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FIGURE 2 | Schematic representation of a range of possible and existing Klotho based senotherapies.
been shown to reduce inhibition of Klotho expression by
TNF/TWEAK signaling in the kidney (86).
(iii) PPAR-c antagonism: The PPAR-γ agonists troglitazone
and ciglitazone, have been shown to increase both Klotho
mRNA and protein expression in vitro. This induction
was blocked by PPAR-c antagonists or by small-interfering
RNA-mediated gene silencing of PPAR-c, suggesting this is
a PPAR-c-dependent mechanism (141).
The angiotensin II type 1 (AT1) receptor is also
important in the aging process. Activation of the AT1
receptor by AngII is implicated in the age-related
developments of hypertension, diabetes, and kidney
disease. Disruption of the AT1 receptor gene in mice
extends life-span and lowers levels of oxidative stress
(142). Angiotensin II-type I receptor agonists have been
used to demonstrate that cyclosporin-induced renal
injury decreased Klotho expression. Yoon et al. have
demonstrated that the Inhibition of the renin–angiotensin
system (RAS) with Losartan restored Klotho expression
in chronic CsA nephropathy (143). RAAS-blockers
which block angiotensin/aldosterone have also been
reported to reverse diminution of Klotho expression in
rodents (5, 20, 144).
(iv) Vitamin D derivatives e.g. paricalcitol: which has been
shown to induce Klotho expression in rodent CKD models
(145, 146). Another is Intermedin—a member of calcitonin
family, which is thought to play a role in angiogenesis
(147). Thiazolidinedione pioglitazone (designed to reduce
insulin resistance by increasing peripheral glucose disposal
and decreasing glucose production) resulted in increased
expression of Klotho and protection against renal injury in
aging (8). Statins have also been shown to induce Klotho
mRNA expression (8).
(v) Exogenous recombinant peptide has also been used to
raise soluble α-Klotho concentrations (20, 148) and
supplementation with the peptide has been shown to
attenuate LPS-induced kidney injury in mice (134).
Numerous studies have shown that similarly to animals
overexpressing α-Klotho, administration of the peptide also
improved renal fibrosis in UUO and bilateral IRI models
(10, 120, 121, 135, 148, 149), cardiac fibrosis in mice
following induced injury (10), and could reduce acute
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to chronic disease progression with development of post
AKI-cardiomyopathy. It was also effective in models of
established injury.
FGF23 Blockade
Blockade of FGF23 using Burosumab, has been demonstrated to
be effective in control and improvement of rickets in patients
with X-linked hypophosphataemia (150, 151). Use in CKD
would require a very narrow and defined window of therapy
to maintain phosphate balance. As FGF23 blockade in animal
models resulted in worsened mineral balance and subsequent
vascular abnormalities (152), more understanding of the FGF23-
phosphate balance required are needed.
Exercise
Numerous studies have demonstrated the effectiveness of
exercise to prevent, reverse, or attenuate premature aging (58,
153, 154). Exercise is associated with regenerative tissue response
(155), reduced atherosclerosis (156), and type-2 diabetes risk
(157). Specifically higher Klotho concentrations are associated
with increased lower limb strength (158), a reduced likelihood
of developing Alzheimers (14), resistance to oxidative stress
(159), and a lower risk of CVD and mortality (160). In pre-
clinical murine models, s-Klotho levels have been associated
with muscle strength and endurance capacity (161). However,
the response to exercise was shown to differ with age (162) and
may be subject to antagonistic pleiotropy. In humans, however,
a long-term exercise programme resulted in increased soluble
Klotho levels being observed in both young and old participants
(162). Levels of soluble Klotho were also shown to be higher in
trained young and old subjects compared to untrained subjects
(163), and aerobic exercise was reported to increase plasma
Klotho levels in young subjects (164). However, in contrast
to these reports despite a functional improvement during a
rehabilitation program, Klotho levels have been reported to
remain unchanged in COPD patients (165). Several components
of physical fitness have been related to related to s-Klotho
plasma levels in the InCHIANTI study, which was a cohort
survey initiated in 1998, primarily to study risk factors and
mechanisms of mobility loss and aging (158, 166, 167). Evidence
from general population cohort studies on the role of beta
or gamma Klotho remains pauce. Optimal and comprehensive
therapeutics strategies targeting Klotho might therefore still need
to ensure address of each of individual isoforms to identify
most the clinically beneficial isoform relative to a particular life
course or disease contex. The concentration of circulating Klotho
required, and that of each of its isoforms, will need to be precisely
identified and genetic variability taken into consideration.
High levels of Klotho could result in hyperparathyroidism and
hypophosphatemic rickets (168), or have other toxic effects.
Timing of Klotho delivery is also critical as soluble Klotho has
been shown to be highly unstable in the blood and urine (169)
and prevention of degradation may be essential.
Numerous compounds have been approved for use in CKD
but with only some positive outcomes seen suggesting the extent
of reactivating and or replacing Klotho and its effects are yet to
be clarified (170).
Nutrition
A number of studies have intimated that Klotho expression is
amenable to nutritional intervention. Age-related changes in
Klotho gene expression, particularly renal Klotho expression,
and vitamin D metabolism can be affected by dietary Pi intake.
As such, nutritional acquisition of Pi can radically affect age-
related health, which opens up an easy avenue for therapy. There
is good rationale for such an approach, as Pi has been linked
to accelerated biological aging (including shortened telomeres,
age related genomic hypomethylation) and poorer renal function
(171) Higher all-cause and cardiovascular mortality risk have also
been associated with Pi intake (172), and to accelerated vascular
aging in the general population (60, 173). Additionally, in pre-
clinical studies, high dietary Pi intake has been demonstrated
to shorten life span in Klotho-deficient mice via activation of
the AKT/mammalian target of rapamycin complex 1 (mTORC1)
(174). Modulation of phosphate in the diet can be problematic.
High protein foods tend to be high in phosphorus, and low
phosphate diets present adherence challenges. Defining diets
acceptable for patients is therefore an important focus. In a
short phosphate restriction trial in patients with ESKD on
hemodialysis, Tsai et al. have compared low and very low
phosphate diets (phosphate:protein ratio 8 vs. 10 mg/g, 2 days
each, separated by 5 days washout). While both diets led to a
decrease in phosphate level, which was more marked with the
very low phosphate diet, no difference was noted in FGF23 levels
between the two diets, which performed similarly in decreasing
FGF23. Supplementation with ketoacid analogs (KA, analogs
of amino acids without the amino group, converted to AA
without additional nitrogen) has been proposed to mitigate the
risk of nutritional disorders associated with very-low protein
diets (VLDP). In a short crossover study in CKD patients (1
week on very low-protein diet 0.3 g/kg/d supplemented with
ketoanalogues; 1 week on low-protein diet 0.6 g/kg/d), Di Iorio
et al. (175) have demonstrated a ∼34% decrease in FGF-23
following the VLPD + ketoanalogues. In patients with CKD 3b-
4, a 14-months low protein diets (0.6–0.8 g protein/kg/d) was
effective in decreasing BMI, at the expense of muscle mass,
with no noted reduction on serum phosphate. In comparison,
ketoacid analog supplementation of the LPD was effective
to maintaining FGF23 and serum Klotho levels, while these
increased and decreased, respectively, in absence of KA (176).
After 14-month of ketoacid-supplemented LPD supplemented
valvular calcification score was also lower compared to patients
following the LPD diet only.
Other pre-clinical studies have indicated that a high fat
diet (HFD) as a surrogate for an energy rich and calorie
dense western diet, results in age-related alterations in renal α-
Klotho expression that could affect the responsiveness of dietary
phosphate to vitamin D metabolism (177).
Alternative nutritional interventions have been designed to
modulate Klotho-FGF23 inter-activity in CKD and thus address
significant features associated with its pathophysiology including
hyperphosphatemia, iron deficiency, and anemia [reviewed by
(178)]. Interventions using iron therapies have displayed varied
impact on Pi toxicity (179), though strategies involving iron-
based phosphate binders do address the dual challenges of
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mitigating the effects of hyperphosphatemia and iron deficiency.
In mice, ferric citrate administration (5% ferric citrate enriched
diet) has led to phosphate binding, correction of iron deficiency,
reduced circulating FGF23, and improved CKD outcomes (180).
Recently, use of a highmagnesium diet has been demonstrated
to prevent extensive vascular calcification in Klotho knock-out
mice, opening up a novel route to tackling clinical VC. These
effects were potentially mediated by reduction of inflammatory
and extracellular matrix remodeling pathways within the aorta.
Notably, serum parathyroid hormone, 1,25-dihydroxyvitamin
D3 and calcium levels were unaffected. However, the high
magnesium reduced bone mineral density and presented treated
animals with possible osteomalacia (181).
Use of magnesium in this context is not unsurprising, given
thatMg2+ is a key factor in the regulation of telomere biology and
its level in the body is diminished inmany diseases of aging (182).
Poor quality diets have been linked with higher level of dietary
phosphate additives, higher fat intake, low vitamin D status, and
lower bioactive-rich fruit and vegetables.
There is a rapidly emerging link between diet and FGF23, with
associations described between diet quality/food (in)security
and FG23 levels. In young adults studied in the context of
coronary artery risk development, this has been tested under the
hypothesis that food insecurity would be associated with intake
of food and drinks with higher levels of phosphate additives, with
potential impact on increased levels of FGF23 as a compensatory
response to higher dietary phosphate intake (183). Pool et al.
(183) have shown that individuals transitioning toward lower
food security (i.e., “developing food insecurity”- defined as being
unable to secure food of sufficient quantity and quality), was
associated with increased odds of high FGF23 expression levels.
This study was however unable to associate phosphorus intake
with odds of elevated FGF23 expression in the cohort, in the
absence of chronic kidney disease. Other pre-clinical studies have
indicated that a high fat diet (HFD), as a surrogate for an energy
rich and calorie dense Western diet, results in strong stimulation
of murine FGF23 via inflammatory pathways, specifically TNFα
formation (184). Correspondingly, Klotho deficiency in mice has
been shown to accelerate and exacerbate HFD-induced arterial
stiffening and hypertension, via down-regulation of vascular
AMPKα expression, and activity (185). Yoshikawa et al. have
also shown an age-related decrease in renal α-Klotho expression
in mice, itself negatively associated with the vitamin D level
response to a high phosphate diet (177).
Secondary analysis of the placebo-controlled Styrian
Vitamin D Hypertension trial (186) trial in 181 adults with
arterial hypertension and a low serum concentration of
25(OH)D (<30 ng/mL) has indicated that while vitamin D
supplementation (2,800 IU daily) had no effect on FGF23
levels in the overall cohort, it did have an effect in subgroups
with a baseline below 20 nl/L. The authors proposed that this
notable rise in FGF23 levels in the low baseline subgroup
could be explained by pronounced elevation of calcitriol levels
and concomitant increased intestinal phosphate absorption.
Systematic reviewing by Charoenngam et al. (187) has
highlighted that the evidence supporting an impact of Vitamin
D on FGF23 is strongest when studies measure intact FGF23
(instead of c-terminal FGF23) with a pooled standardized mean
difference (SMD) of 0.36 (95%CI, 0.14, 0.57; p = 0.001; I2 of
36%) in vitamin D deficient individuals.
In a small sample of middle-aged sedentary adults (n =
74) enrolled in the FIT-AGEING study, a negative association
has been demonstrated between total alcoholic intake and S-
Klotho plasma levels (β = −17.031; R2 = 0.096, P = 0.013),
even when adjusted for body composition parameters (188).
Pre-clinical models have suggested a role for dietary bio-actives
in Klotho expression. Specifically, Hsu et al. suggest that this
can be achieved with resveratrol administration in vitro (NRK-
52E cells) and in vivo (mouse kidney) with involvement of
the ATF3/c-Jun pathway (189). However, subsequent analysis
in the FIT-AGEING cohort was only able to show a weak
association between the Dietary Inflammatory Index (DII) (190)
or adherence to the Mediterranean Diet (191) with soluble
Klotho. These associations disappeared when corrected for Lean
Mass Index. Of particular interest is the role of dietary fiber in
the prevention of renal function decline in CKD patients. With
a low fruit and vegetable intake, fiber, and polyphenolic intake
is typically reduced, which could have a direct impact on the
functionality of the gut microbiota. In a randomized control
trial in 52 patients with CKD (stages 3–5), supplementation
with 50 g oats daily (rich in the soluble fiber beta-glucan and
polyphenolics) for 8 weeks, did have a beneficial impact on
serum potassium, but not Klotho levels or parathyroid hormone
(192). There is a lack of high quality trials with well-defined
inflammatory, iron and vitamin D status focusing on dietary
bioactive intake administrated in food or supplemental forms,
and new evidence in this field will facilitate improved dietary
guidance for kidney health and healthy aging.
The Gut Microbiota
The gut microbiota has emerged as a significant contributory
factor to age related health [reviewed in (35)], where it appears
to have a significant effect on the epigenetic landscape of
aging. An understanding of any relationship between the gut
microbiota and Klotho remains embryonic. However, there is
an emerging indirect linkage based on the modulation of cell
stress responses via processing of dietary acquired (poly)phenolic
acids, which are potent Nrf2 agonists (193). The relationship
between the microbiota and Nrf2 expression is an emerging
therapeutic axis for a range treatment of the diseasome of
aging and thus pertinent to Klotho. The transcription factor
Nrf 2 controls a battery of over 390 cytoprotective genes and
its expression is diminished with increasing age. Numerous
nutritional intervention strategies are already in trial to enhance
its age-related expression [reviewed in (32, 194)]. Furthermore,
pre-clinical studies are supportive on such an approach to
tackle CKD, via indirect up-regulation of Klotho achieved
via Nrf2 agonism. Indeed, use of a synthetic Nrf2 agonist
has already been demonstrated to induce Klotho expression
and mitigate the effects of CKD in mice. Klotho per se (i.e.,
direct Klotho agonism) has not featured as a mediator of such
effects, though this is intuitive with respect to β-Klotho, as
its FGF19 substrate is secreted by bile acids produced by gut
microbiota (5).
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There is also an emerging relationship between the gut
microbiota and the vitamin D/FGF23 axis. In murine models,
Bora et al. (195) have demonstrated that antibiotic treatment
increased vitamin D status, which in turn increased FGF23 levels
after 14 days. However, the treatment effect on vitamin D was
partly independent from the microbiota (as shown in GF mice)
and potentially indicative of a direct impact on absorption.
CONCLUSIONS
The emerging field of Geroscience seeks to address the cellular
and molecular mechanisms underpinning the aging process and
to understand how, when and why these become dysregulated,
as the diseasome of aging manifests. Modulation of Klotho has
emerged as a prime target for interventions within this space,
having the potential to complement and synergise with other
emerging therapies, including senolytics and live biotherapeutics,
as well as more conventional pharmaceuticals. The ability to
couple any emerging therapies with nutritional and exercise
based approaches, offers a more holistic means of translating
these to the general population and thus improving healthspan.
Applications to age related diseases, such as CKD are exciting,
and have already demonstrated clinical benefit with more
promised to come.
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